跳到正文
原文
Endpoints News 生物医药· ENDPOINTS·· 2026-10-20AI 评分49

辉瑞终止PF-06835375治疗特发性血小板减少性紫癜的II期临床试验

Pfizer ends Phase 2 autoimmune study; Lycia aims for $227M IPO

AI 导读

辉瑞(Pfizer)终止了针对罕见自身免疫疾病特发性血小板减少性紫癜(primary immune thrombocytopenia)的PF-06835375 II期临床试验。官方消息指出,该终止决定源于联邦临床监管机构(federal clinical …)的介入。文中未说明终止的具体临床原因(如安全性事件或疗效不足),也未提供已发布的完整研究数据。

正文

Pfiz­er halts Phase 2 au­toim­mune tri­al: The study was test­ing a pro­gram called PF-06835375 in the rare au­toim­mune dis­or­der pri­ma­ry im­mune throm­bo­cy­tope­nia. The fed­er­al clin­i­cal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news